This website is intended for UK healthcare professionals only
Prescribing information can be found here
A recommended EASD consensus report 2019 SGLT2i logo

The 1st SGLT2i also licensed to treat
diabetic kidney disease (DKD) in T2DM

Now for treatment of patients with severe albuminuria from
early identification until dialysis or renal transplantation

1st

Watch the animation below on the first published renal outcomes study with an SGLT2i. 1

slowing of renal disease progression - reduction in admissions for heart failure - reduction in cardiovascular events

The CREDENCE trial and its value from a clinical perspective

David Wheeler

David Wheeler, Professor of Kidney Medicine, University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust looks at the findings of the CREDENCE study and the impact of Invokana on the progression of chronic kidney disease (CKD) and cardiovascular complications in patients with both type 2 diabetes and CKD.

Watch video
John Wilding

Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree discusses the CREDENCE study, and how Invokana has emerged as first new treatment to reduce the progression of chronic kidney disease in type 2 diabetes for 20 years.

Watch video
Professor Philip Kalra

Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester and Professor John Wilding, Professor of Endocrinology at the University of Liverpool, and Honorary Consultant Diabetologist, University Hospital, Aintree present their key take home messages from the CREDENCE trial.

Watch video
Julie Brake

Julie Brake, Diabetes Nurse Consultant, Royal Liverpool University Hospital NHS Trust, and Professor Philip Kalra, Consultant Nephrologist at Salford Royal Foundation Trust, Manchester discuss the clinical value of the CREDENCE study and implications for patients with type 2 diabetes and chronic kidney disease.

Watch video

Protect T2DM patients against diabetic kidney disease (DKD) progression

In CREDENCE, Invokana showed a:

30% relative risk reduction in the primary
composite outcome compared to placebo + SoC.2
HR: 0.70 (95% CI, 0.57–0.84), p<0.0001.
ARR: 18 fewer events per 1000 patient-years

NNT (2.5 yrs)

Reduce future kidney damage and slow the decline of kidney function

In CREDENCE, Invokana showed a:

31% reduction in the amount of albuminuria.
Calculated by the geometric mean of the urinary-albumin creatinine ratio, compared to placebo + SoC.1 (95%CI, 26-35%)
Kidney damage
60% reduction in rate of eGFR decline

Invokana reduced the rate of kidney function (eGFR) decline by 60%.1

In the chronic phase of the trial (from week 3 until the trial end)
Difference 2.74/year (95% CI, 2.37-3.11)

References
  1. Reference 16
  2. Reference 7